Mostrar o rexistro simple do ítem

dc.contributor.authorDelgado-Jiménez, Juan F.
dc.contributor.authorSegovia-Cubero, Javier
dc.contributor.authorAlmenar-Bonet, Luis
dc.contributor.authorJuan-Bagudá, Javier de
dc.contributor.authorLara-Padrón, Antonio
dc.contributor.authorGarcía-Pinilla, José Manuel
dc.contributor.authorBonilla-Palomas, Juan Luis
dc.contributor.authorLópez-Fernández, Silvia
dc.contributor.authorMirabet-Pérez, Sonia
dc.contributor.authorGómez-Otero, Inés
dc.contributor.authorCastro-Fernández, Antonio
dc.contributor.authorDíaz-Molina, Beatriz
dc.contributor.authorGoirigolzarri-Artaza, Josebe
dc.contributor.authorRincón-Pérez, Luis Miguel
dc.contributor.authorPascual-Figal, Domigo A.
dc.contributor.authorAnguita-Sánchez, Manuel
dc.contributor.authorMuñiz, Javier
dc.contributor.authorCrespo-Leiro, María Generosa
dc.date.accessioned2022-03-02T08:52:37Z
dc.date.available2022-03-02T08:52:37Z
dc.date.issued2022-02-22
dc.identifier.citationDelgado-Jiménez, J.F.; Segovia-Cubero, J.; Almenar-Bonet, L.; de Juan-Bagudá, J.; Lara-Padrón, A.; García-Pinilla, J.M.; Bonilla-Palomas, J.L.; López-Fernández, S.; Mirabet-Pérez, S.; Gómez-Otero, I.; Castro-Fernández, A.; Díaz-Molina, B.; Goirigolzarri-Artaza, J.; Rincón-Díaz, L.M.; Pascual-Figal, D.A.; Anguita-Sánchez, M.; Muñiz, J.; Crespo-Leiro, M.G. Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics. J. Clin. Med. 2022, 11, 1170.es_ES
dc.identifier.issn2077-0383
dc.identifier.urihttp://hdl.handle.net/2183/29857
dc.description.abstract[Abstract] Hyperkalaemia is a growing concern in the treatment of patients with heart failure and reduced ejection fraction (HFrEF) as it limits the use of some prognostic-modifying drugs and has a negative impact on prognosis. The objective of the present study was to estimate the prevalence of hyperkalaemia in outpatients with HFrEF and its impact on achieving optimal medical treatment. For this purpose, a multicentre, prospective, and observational study was carried out on consecutive HFrEF patients who were monitored as outpatients in heart failure (HF) units and who, in the opinion of their doctor, received optimal medical treatment. A total of 565 HFrEF patients were included from 16 specialised HF units. The mean age was 66 ± 12 years, 78% were male, 45% had an ischemic cause, 39% had atrial fibrillation, 43% were diabetic, 42% had a glomerular filtration rate < 60 mL/min/1.7 m2, and the mean left ventricular ejection fraction was 31 ± 7%. Treatment at the study entry included: 76% on diuretics, 13% on ivabradine, 7% on digoxin, 18.9% on angiotensin-conversing enzyme inhibitors (ACEi), 11.3% on angiotensin receptors blockers (ARBs), 63.8% on angiotensin-neprilysin inhibitors (ARNi), 78.5% on mineralocorticoid receptor antagonists (MRAs), and 92.9% on beta-blockers. Potassium levels in the baseline analysis were: ≤5 mEq/L = 80.5%, 5.1–5.4 mEq/L = 13.8%, 5.5–5.9 mEq/L = 4.6%, and ≥6 mEq/L = 1.06%. Hyperkalaemia was the reason for not prescribing or reaching the target dose of an MRAs in 34.8% and 12.5% of patients, respectively. The impact of hyperkalaemia on not prescribing or dropping below the target dose in relation to ACEi, ARBs, and ARNi was significantly less. In conclusion, hyperkalaemia is a frequent problem in the management of patients with HFrEF and a limiting factor in the optimisation of medical treatment.es_ES
dc.description.sponsorshipAstraZeneca Farmacéutica; ESR-17-13244es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relation.urihttps://doi.org/10.3390/jcm11051170es_ES
dc.rightsCreative Commons Attribution 4.0 International Licence (CC-BY 4.0)es_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectHyperkalaemiaes_ES
dc.subjectHeart failurees_ES
dc.subjectMedical treatmentes_ES
dc.titlePrevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristicses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES
UDC.journalTitleJournal of Clinical Medicinees_ES
UDC.volume11es_ES
UDC.startPage1170es_ES
dc.identifier.doi10.3390/jcm11051170


Ficheiros no ítem

Thumbnail
Thumbnail

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem